ES2167745T3 - Suspensiones acuosas de esteres de acidos grasos de 9-hidroxi-risperidona. - Google Patents
Suspensiones acuosas de esteres de acidos grasos de 9-hidroxi-risperidona.Info
- Publication number
- ES2167745T3 ES2167745T3 ES97923912T ES97923912T ES2167745T3 ES 2167745 T3 ES2167745 T3 ES 2167745T3 ES 97923912 T ES97923912 T ES 97923912T ES 97923912 T ES97923912 T ES 97923912T ES 2167745 T3 ES2167745 T3 ES 2167745T3
- Authority
- ES
- Spain
- Prior art keywords
- composition
- risperidona
- esteres
- hidroxi
- fatty acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96201429 | 1996-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2167745T3 true ES2167745T3 (es) | 2002-05-16 |
Family
ID=8224016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97923912T Expired - Lifetime ES2167745T3 (es) | 1996-05-20 | 1997-05-12 | Suspensiones acuosas de esteres de acidos grasos de 9-hidroxi-risperidona. |
Country Status (37)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2245252A1 (es) * | 2004-06-15 | 2005-12-16 | Farmalider, S.A. | Solucion acuosa de risperidona para administracion oral. |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA72189C2 (uk) * | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| CA2321924A1 (en) * | 1998-02-25 | 1999-09-02 | Abbott Laboratories | Butorphanol sustained release formulations |
| WO2000010572A1 (en) * | 1998-08-18 | 2000-03-02 | Sepracor Inc. | Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine |
| EE05022B1 (et) | 1999-03-31 | 2008-06-16 | Janssen Pharmaceutica N.V. | Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| EP1982980A1 (en) * | 2000-08-14 | 2008-10-22 | Teva Pharmaceutical Industries Ltd. | Crystalline form of risperidone |
| US7666445B2 (en) * | 2000-10-20 | 2010-02-23 | The Trustees Of The University Of Pennsylvania | Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use |
| GB0216416D0 (en) * | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| AU2003256844A1 (en) * | 2002-07-29 | 2004-02-16 | Alza Corporation | Methods and dosage forms for controlled delivery of paliperidone |
| GB0322994D0 (en) * | 2003-10-01 | 2003-11-05 | Novartis Ag | Organic compounds |
| JP4836797B2 (ja) | 2003-10-23 | 2011-12-14 | 大塚製薬株式会社 | 放出制御性無菌注射アリピプラゾール製剤および方法 |
| US8221778B2 (en) | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| JP5306599B2 (ja) * | 2004-01-12 | 2013-10-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 長期間送達製剤 |
| US8329203B2 (en) * | 2004-01-12 | 2012-12-11 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| CN101163702B (zh) | 2005-04-25 | 2011-09-07 | 詹森药业有限公司 | 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法 |
| PL116330U1 (en) | 2005-10-31 | 2007-04-02 | Alza Corp | Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation |
| CA2670821C (en) | 2006-08-09 | 2012-05-15 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
| EP2154138B1 (en) * | 2007-04-19 | 2015-08-19 | Youxin Li | Novel compounds for treatment of psychotic disorders, preparation methods and uses thereof |
| WO2008133908A2 (en) | 2007-04-23 | 2008-11-06 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
| US20090076035A1 (en) * | 2007-09-15 | 2009-03-19 | Protia, Llc | Deuterium-enriched paliperidone |
| US9439906B2 (en) | 2007-12-19 | 2016-09-13 | Janssen Pharmaceutica Nv | Dosing regimen associated with long acting injectable paliperidone esters |
| US20090209757A1 (en) * | 2008-01-10 | 2009-08-20 | Santiago Ini | Processes for the preparation and purification of paliperidone palmitate |
| EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
| SG10201703039SA (en) | 2008-09-04 | 2017-05-30 | Amylin Pharmaceuticals Llc | Sustained release formulations using non-aqueous carriers |
| PL2462246T3 (pl) | 2009-09-28 | 2018-02-28 | Intarcia Therapeutics, Inc | Szybkie ustalenie i/lub zakończenie dostarczania leku zasadniczo w stanie równowagi dynamicznej |
| AU2010313290A1 (en) | 2009-10-30 | 2012-05-17 | Janssen Pharmaceutica Nv | Dosing regimen associated with long-acting injectable paliperidone esters |
| WO2011074017A1 (en) * | 2009-12-17 | 2011-06-23 | Alkem Laboratories Ltd. | A novel process for the preparation of paliperidone |
| TWI577377B (zh) | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| CN107595771A (zh) | 2010-10-18 | 2018-01-19 | 大日本住友制药株式会社 | 注射用缓释制剂 |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| ES2587527T3 (es) * | 2011-05-31 | 2016-10-25 | RAMAMOHAN RAO, Davuluri | Preparación de 3-[2-[4-((6-fluoro-1,2-bencisoxazol-3-il)-l-piperidinil)-6,7,8,9-tetrahidro-9-hidroxi-2-metil-4H-pirido[1,2 a]-primidin-4-ona (paliperidona) y palmitato de paliperidona |
| WO2013046225A2 (en) * | 2011-08-10 | 2013-04-04 | Glenmark Generics Limited | Process for the preparation of paliperidone palmitate |
| CN102993200B (zh) * | 2011-09-10 | 2016-02-03 | 鲁翠涛 | 帕潘立酮氨基酸酯及其制备方法 |
| CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US10525057B2 (en) | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| WO2016164218A1 (en) | 2015-04-07 | 2016-10-13 | Janssen Pharmaceuticals, Inc. | Dosing regimen for missed doses for long-acting injectable paliperidone esters |
| MA44390A (fr) | 2015-06-03 | 2019-01-23 | Intarcia Therapeutics Inc | Systèmes de mise en place et de retrait d'implant |
| KR20240037175A (ko) | 2016-05-16 | 2024-03-21 | 인타르시아 세라퓨틱스 인코포레이티드 | 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법 |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
| LT4025189T (lt) | 2020-11-30 | 2024-07-10 | Janssen Pharmaceutica Nv | Dozavimo režimai, susiję su prailginto atpalaidavimo paliperidono palmitato injekcinėmis vaisto formomis |
| HUE067584T2 (hu) | 2020-11-30 | 2024-10-28 | Janssen Pharmaceutica Nv | Eljárások paliperidon-palmitát formulációk reszuszpenziójának biztosítására |
| SI4025188T1 (sl) | 2020-11-30 | 2024-03-29 | Janssen Pharmaceutica Nv | Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem |
| CA3203448A1 (en) | 2020-11-30 | 2022-06-02 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
| HUP2100259A1 (hu) | 2021-07-07 | 2023-01-28 | Richter Gedeon Nyrt | Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények |
| MX2024002215A (es) | 2021-08-20 | 2024-05-10 | Janssen Pharmaceutica Nv | Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2000786C (en) * | 1988-11-07 | 1999-01-26 | Cornelus G. M. Janssen | 3-piperidinyl-1,2-benzisoxazoles |
| US5158952A (en) * | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| US5254556A (en) * | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
| TW376319B (en) * | 1993-04-28 | 1999-12-11 | Janssen Pharmaceutica Nv | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine |
| DK0729357T3 (da) * | 1993-11-19 | 2005-06-06 | Janssen Pharmaceutica Nv | Mikroindkapslede 1,2-benzazoler |
| PT729353E (pt) * | 1993-11-19 | 2002-07-31 | Alkermes Inc | Preparacao de microparticulas biodegradaveis contendo um agente biologicamente activo |
| US5650173A (en) * | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
| MX9709451A (es) * | 1995-06-06 | 1998-02-28 | Hoechst Marion Roussel Inc | Derivados de benzisoxazol e indazol como agentes antipsicoticos. |
| US5792477A (en) * | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
-
1997
- 1997-05-01 TW TW086105768A patent/TW487572B/zh not_active IP Right Cessation
- 1997-05-12 BR BRPI9706824-1B8A patent/BR9706824B8/pt not_active IP Right Cessation
- 1997-05-12 CZ CZ19981401A patent/CZ291284B6/cs not_active IP Right Cessation
- 1997-05-12 DE DE69708284T patent/DE69708284T2/de not_active Expired - Lifetime
- 1997-05-12 SK SK620-98A patent/SK284013B6/sk not_active IP Right Cessation
- 1997-05-12 NZ NZ330369A patent/NZ330369A/xx not_active IP Right Cessation
- 1997-05-12 CN CN97191494A patent/CN1093762C/zh not_active Expired - Lifetime
- 1997-05-12 EE EE9800136A patent/EE03594B1/xx active Protection Beyond IP Right Term
- 1997-05-12 CA CA002236691A patent/CA2236691C/en not_active Expired - Lifetime
- 1997-05-12 DE DE201112100027 patent/DE122011100027I1/de active Pending
- 1997-05-12 HU HU9901319A patent/HU224025B1/hu active Protection Beyond IP Right Term
- 1997-05-12 WO PCT/EP1997/002504 patent/WO1997044039A1/en active IP Right Grant
- 1997-05-12 SI SI9730272T patent/SI0904081T1/xx unknown
- 1997-05-12 AT AT97923912T patent/ATE208619T1/de active
- 1997-05-12 PT PT97923912T patent/PT904081E/pt unknown
- 1997-05-12 KR KR10-1998-0703629A patent/KR100358373B1/ko not_active Expired - Lifetime
- 1997-05-12 EA EA199800531A patent/EA000536B1/ru not_active IP Right Cessation
- 1997-05-12 EP EP97923912A patent/EP0904081B1/en not_active Expired - Lifetime
- 1997-05-12 ES ES97923912T patent/ES2167745T3/es not_active Expired - Lifetime
- 1997-05-12 US US09/180,659 patent/US6077843A/en not_active Expired - Lifetime
- 1997-05-12 TR TR1998/00923T patent/TR199800923T2/xx unknown
- 1997-05-12 AU AU29559/97A patent/AU715572B2/en not_active Expired
- 1997-05-12 DK DK97923912T patent/DK0904081T3/da active
- 1997-05-12 PL PL97327995A patent/PL188309B1/pl unknown
- 1997-05-12 JP JP54150097A patent/JP3274687B2/ja not_active Expired - Lifetime
- 1997-05-12 IL IL12455197A patent/IL124551A/xx not_active IP Right Cessation
- 1997-05-19 AR ARP970102112A patent/AR007194A1/es active IP Right Grant
- 1997-05-19 ID IDP971649A patent/ID16927A/id unknown
- 1997-05-19 ZA ZA974331A patent/ZA974331B/xx unknown
- 1997-05-19 MY MYPI97002172A patent/MY126302A/en unknown
- 1997-05-20 HR HR970276A patent/HRP970276B1/xx not_active IP Right Cessation
- 1997-12-05 UA UA98052747A patent/UA61898C2/uk unknown
-
1998
- 1998-04-30 NO NO19981984A patent/NO315931B1/no not_active IP Right Cessation
- 1998-05-12 BG BG102443A patent/BG62684B1/bg unknown
- 1998-06-15 MX MX9804816A patent/MX9804816A/es unknown
-
2002
- 2002-04-25 CY CY0200021A patent/CY2270B1/xx unknown
-
2011
- 2011-07-20 LU LU91842C patent/LU91842I2/fr unknown
- 2011-08-18 CY CY2011011C patent/CY2011011I1/el unknown
- 2011-08-18 HU HUS1100013C patent/HUS1100013I1/hu unknown
- 2011-08-29 NO NO2011015C patent/NO2011015I2/no unknown
- 2011-09-02 FR FR11C0035C patent/FR11C0035I2/fr active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2245252A1 (es) * | 2004-06-15 | 2005-12-16 | Farmalider, S.A. | Solucion acuosa de risperidona para administracion oral. |
| WO2005123085A1 (es) * | 2004-06-15 | 2005-12-29 | Farmalider, S.A. | Solución acuosa de risperidona para administración oral |
| ES2245252B1 (es) * | 2004-06-15 | 2007-03-01 | Farmalider, S.A. | Solucion acuosa de risperidona para administracion oral. |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2167745T3 (es) | Suspensiones acuosas de esteres de acidos grasos de 9-hidroxi-risperidona. | |
| EA200000541A1 (ru) | Водные суспензии субмикронных 9-гидроксирисперидоновых сложных эфиров жирных кислот | |
| ES2058109T3 (es) | Un procedimiento para la preparacion de una composicion farmaceutica antimicrobiana topica. | |
| BR9809655A (pt) | Uso de derivados do ácido fumárico | |
| SE8503664L (sv) | Ett system for tillforsel av lekemedel | |
| BR0209320A (pt) | ésteres de uridina farmaceuticamente ativos | |
| ES2185758T3 (es) | Utilizacion de esteres grasos etoxilados como compuestos auto-emulsionables. | |
| UA41502C2 (uk) | Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання | |
| GT199800150A (es) | Derivados de resorcinol. | |
| HUP0101580A2 (hu) | Gélesedő gyógyászati készítmények | |
| ES2123654T3 (es) | Carbapenems que contienen un grupo fenilo substituido con carboxi, procesos para su preparacion, productos intermedios y uso como antibioticos. | |
| MX9306303A (es) | Derivados de acidos carboxilicos, medicamentos que contienen estos compuestos y procedimientos para su preparacion. | |
| ES2089011T3 (es) | Excipiente lipidico de administracion nasal y aplicacion topica. | |
| KR100397034B1 (ko) | 비강투여용비무기식염용액 | |
| BRPI0107731B8 (pt) | método para purificar daptomicina | |
| KR960700062A (ko) | 산성 pH에서의 안정성을 개선시키기 위해 변형된 올리고누클레오티드(OLIGONUCLEOTIDES MODIFIED TO IMPROVE STABILITY AT ACIC pH) | |
| BRPI0400214A (pt) | Composições e aplicações farmacêuticas para a obtenção confiável de nìveis aceitáveis de testosterona no soro | |
| IL97796A0 (en) | Pharmaceutical compositions containing n-alkylated 1,4-dihydropyridine-dicarboxylic acid esters,certain such compounds and their preparation | |
| WO1987004926A3 (en) | Method of modifying the lipid structure of cell membranes and pharmaceutical compositions for use therein | |
| ES2245004T3 (es) | Inhibicion viral mediante alcoholes, alcanos, acidos grasos y amidas de cadena larga. | |
| ES2093782T3 (es) | Piridazindionas y su uso en el tratamiento de trastornos neurologicos. | |
| AR004625A1 (es) | Composicion de un oseo activo que comprende una sustancia de un oseo activo y un carrier bilogico de dicha sustancia,composicion farmaceutica que comprende dicha composicion de un oseo-activo,y uso de dicha composicion para la preparacion de un medicamento | |
| AR005102A1 (es) | Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento. | |
| KR930702965A (ko) | 생체이용성이 개선된 프로부콜 함유 제약 조성물 | |
| IT1253832B (it) | Derivati di gangliosidi |